OnKure Therapeutics, Inc.
Business
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines targeting biologically validated drivers of cancer. Its lead candidate OKI-219 is a selective small-molecule inhibitor of mutated PI3Kα designed for advanced breast cancer. The company is also pursuing a pan-mutant PI3Kα inhibitor and a vascular malformations program. OnKure retains worldwide rights to all programs and operates clinical trial sites globally.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 48 | 44 | 32 | 38 | 28 | |
| General and administrative | 15 | 11 | 5 | 16 | 12 | |
| Total operating expenses | 63 | 54 | 37 | 54 | 40 | |
| Loss from operations | −63 | −54 | −37 | −54 | −40 | |
| Interest income | 3 | 2 | 2 | — | — | |
| Interest and other expense | −8,000 | −300,000 | — | — | — | |
| Total other income (expense) | 3 | 2 | 2 | — | — | |
| Net loss and comprehensive loss | −60 | −53 | −35 | −52 | −40 | |
| Net loss per share attributable to common stockholders: Basic | −4.4 | −15.28 | −124.41 | −2.12 | −2.19 | |
| Net loss per share attributable to common stockholders: diluted | −4.4 | −15.28 | −124.41 | −2.12 | −2.19 | |
| Weighted average shares outstanding: Basic | 14 | 3 | 283,817 | 24 | 18 | |
| Weighted average shares outstanding: diluted | 14 | 3 | 283,817 | 24 | 18 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 59 | 111 | 30 | 20 | 125 | |
| Prepaid expenses and other current assets | 2 | 2 | 4 | 5 | 6 | |
| Total current assets | 61 | 113 | 34 | 106 | 154 | |
| Property and equipment, net | 618,000 | 1 | 1 | 453,000 | 212,000 | |
| Operating lease right-of-use asset | 387,000 | 770,000 | 478,000 | 1 | — | |
| Other assets | 273,000 | 109,000 | 58,000 | 84,000 | 78,000 | |
| Total assets | 62 | 115 | 36 | 108 | 154 | |
| Accounts payable | 1 | 3 | 3 | 2 | 2 | |
| Accrued expenses and other current liabilities | 4 | 7 | — | — | — | |
| Operating lease liabilities, current portion | 549,000 | 536,000 | 208,000 | 404,000 | — | |
| Total current liabilities | 6 | 11 | 7 | 7 | 6 | |
| Long-term operating lease liabilities | — | 549,000 | 466,000 | 1 | — | |
| Other long-term liabilities | 12,000 | — | — | — | 167,000 | |
| Total liabilities | 6 | 11 | 8 | 8 | 7 | |
| Commitments and contingencies | — | — | — | — | — | |
| Additional paid-in capital | 270 | 259 | 209,000 | 237 | 232 | |
| Accumulated deficit | −214 | −155 | −102 | −137 | −85 | |
| Total stockholders' equity | 56 | 104 | −102 | −54 | 147 | |
| Total liabilities and stockholders' equity | 62 | 115 | 36 | 108 | 154 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Share-based compensation expense | 12 | 5 | 199,000 | 4 | 4 | |
| Depreciation and amortization | 447,000 | 459,000 | 417,000 | 88,000 | 50,000 | |
| Amortization of right-of-use asset - operating | 383,000 | 203,000 | 143,000 | — | — | |
| Loss on disposal of property and equipment | 6,000 | — | — | — | — | |
| Amortization of debt issuance costs | — | 142,000 | — | — | — | |
| Non-cash interest expense | — | 120,000 | — | — | — | |
| Loss on sales of available-for-sale securities | — | 54,000 | — | 17,000 | — | |
| Prepaid and other assets | 289,000 | 2 | −1 | 878,000 | −5 | |
| Accounts payable, accrued and other liabilities | −5 | −6 | 2 | 518,000 | 2 | |
| Lease liabilities | −536,000 | −281,000 | −210,000 | −437,000 | — | |
| Other long-term liabilities | 12,000 | — | — | — | — | |
| Net cash used in operating activities | −52 | −51 | −35 | −47 | −38 | |
| Proceeds from sales of marketable securities | — | 16 | — | — | — | |
| Purchases of property and equipment | −46,000 | −52,000 | −246,000 | −346,000 | −198,000 | |
| Net cash (used in) provided by investing activities | −46,000 | 16 | −246,000 | −58 | −23 | |
| Cash acquired in connection with the reverse recapitalization | — | 58 | — | — | — | |
| Payment of reverse recapitalization transaction costs | −40,000 | −2 | — | — | — | |
| Proceeds from issuance of convertible notes payable | — | 6 | — | — | — | |
| Payment of issuance costs associated with the issuance of convertible notes payable | — | −142,000 | — | — | — | |
| Proceeds from sale of stock under the employee stock purchase plan | 240,000 | — | — | — | — | |
| Proceeds from the issuance of common stock for exercises of stock options | — | 26,000 | — | — | 556,000 | |
| Net cash provided by financing activities | 163,000 | 116 | 53 | 471,000 | 132 | |
| Net decrease in cash and cash equivalents | −52 | 81 | 18 | −105 | 71 | |
| Conversion of Series C Preferred Stock | — | 130 | — | — | — | |
| Conversion of convertible note payable | — | 6 | — | — | — | |
| Assets acquired in connection with the reverse recapitalization | — | 17 | — | — | — | |
| Other liabilities assumed in connection with the reverse recapitalization | — | 9 | — | — | — | |
| Reverse recapitalization transaction costs included in accounts payable | — | 40,000 | — | — | — | |
| Concurrent Financing issuance costs included in accounts payable | — | 37,000 | — | — | — | |
| Concurrent Financing issuance costs paid by Reneo prior to Merger | — | 89,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is OnKure Therapeutics, Inc.'s CIK number?
OnKure Therapeutics, Inc.'s SEC CIK number is 0001637715 (1637715). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find OnKure Therapeutics, Inc.'s SEC filings?
All of OnKure Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did OnKure Therapeutics, Inc. last report earnings?
OnKure Therapeutics, Inc. (OKUR) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-206396). This is OnKure Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is OnKure Therapeutics, Inc.'s most recent earnings 8-K?
OnKure Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-206396. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View OnKure Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →